angiotensin ii has been researched along with imatinib mesylate in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cox, AJ; Gilbert, RE; Gow, RM; Kelly, DJ; Kemp, BE; Zhang, Y | 1 |
| Akizawa, T; Hirai, Y; Iyoda, M; Kuno, Y; Shibata, T | 1 |
| Graciano, ML; Mitchell, KD | 1 |
| Chen, C; Chen, X; Ding, G; Liang, W; Liu, Y; Ren, Z; Singhal, PC; Zha, D | 1 |
| Dugic, E; Eriksson, P; Mäyränpää, MI; Roy, J; Vikingsson, S; Vorkapic, E; Wågsäter, D | 1 |
| Balboa Ramilo, A; Becirovic-Agic, M; Mani, K; Petri, MH; Wågsäter, D; Wanhainen, A | 1 |
6 other study(ies) available for angiotensin ii and imatinib mesylate
| Article | Year |
|---|---|
Platelet-derived growth factor receptor transactivation mediates the trophic effects of angiotensin II in vivo.
Topics: Angiotensin II; Animals; Benzamides; Cells, Cultured; Imatinib Mesylate; Male; Mesenteric Arteries; Muscle, Smooth, Vascular; Organ Size; Phosphorylation; Piperazines; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, Platelet-Derived Growth Factor; Receptors, Transforming Growth Factor beta; RNA, Messenger; Transcriptional Activation | 2004 |
Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease.
Topics: Angiotensin II; Animals; Benzamides; Collagen; Fibroblasts; Hypertrophy; Imatinib Mesylate; Kidney; Kidney Failure, Chronic; Male; Mesangial Cells; Nephrectomy; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Platelet-Derived Growth Factor beta; Treatment Outcome | 2011 |
Imatinib ameliorates renal morphological changes in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension.
Topics: Albuminuria; Angiotensin II; Animals; Benzamides; Cytochrome P-450 CYP1A1; Hypertension, Malignant; Imatinib Mesylate; Indoles; Kidney; Male; Piperazines; Pyrimidines; Rats; Rats, Transgenic; Receptors, Platelet-Derived Growth Factor; Renin | 2012 |
c-Abl mediates angiotensin II-induced apoptosis in podocytes.
Topics: Angiotensin II; Animals; Apoptosis; Benzamides; Cell Line, Transformed; Gene Expression Regulation; Imatinib Mesylate; Infusion Pumps, Implantable; Male; Mice; Phosphorylation; Piperazines; Podocytes; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Rats; Rats, Sprague-Dawley; RNA, Small Interfering; Signal Transduction; Tumor Suppressor Protein p53 | 2013 |
Imatinib treatment attenuates growth and inflammation of angiotensin II induced abdominal aortic aneurysm.
Topics: Angiotensin II; Animals; Aorta; Aortic Aneurysm, Abdominal; Apolipoproteins E; Apoptosis; CD3 Complex; Chymases; Humans; Imatinib Mesylate; Inflammation; Male; Mast Cells; Mice; Mice, Knockout; Muscle, Smooth, Vascular; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Signal Transduction | 2016 |
The tyrosine kinase inhibitor Bosutinib does not inhibit angiotensin II-induced abdominal aortic aneurysm: Validation of the importance of PDGFR and c-Kit tyrosine kinases by Imatinib.
Topics: Angiotensin II; Aniline Compounds; Aortic Aneurysm, Abdominal; Humans; Imatinib Mesylate; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Quinolines | 2022 |